Live Breaking News & Updates on Aqurat Fondkommission|Page 2

Stay updated with breaking news from Aqurat fondkommission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BBS' rights offering ongoing – The subscription period ends on 26 June in Sweden and 28 June in Finland

BBS-Bioactive Bone Substitutes Plc, Investor News, 22 June 2023 at 9.00 a.m. EEST BBS-Bioactive Bone Substitutes Plc is currently running a rights offering of approximately maximum EUR 2.9 million. Net proceeds from the offering will be used inter alia . ....

Ilkka Kangasniemi , Bone Substitutes Plc , Bioactive Bone Substitutes Plc , Investor News , Sweden Aqurat Fondkommission , Aqurat Fondkommission , Nasdaq First North Growth Market Finland ,

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden and who wish to accept the proposed merger consideration must carry out closer investigations regarding the applicable legislation and possible tax consequences.
The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, intend to merge and create a powerful pharmaceutical company for drug development for the treatment of cancer and infectious diseases. The merged company (Hamlet Biopharma) gets a portfolio with a total of ten pharmaceutical projects, of which three projects are in phase II, where two of the projects already have positive ....

United Kingdom , Hong Kong , United States , Great Britain , Selectimmune Pharma , Jan Zetterberg , Carl Johan Wachtmeister , Martin Erixon , Fredrik Herslow , Helena Lomberg , Catharina Svanborg , Linnane Pharma , Olle Jonsson , Hans Nygren , Falkenborn Advokatbyr , Nordnet Pensionsf , Hazina Ljungman , Swedish Companies , Swedish Companies Registration Office The Completion , Swedish Securities Council , Commerce Stock Exchange Committee , Patent Group , Rolf Karlsson Fv Group , Exchange Commission , Swedish Companies Registration Office , Hamlet Pharma ,

Nasdaq Stockholm AB: Listing of RanLOS AB (publ), on Nasdaq First North Growth Market (181/23)

Nasdaq Stockholm AB has assessed that RanLOS AB (publ), company registration
number 559046-1116, fulfills Nasdaq First North Growth Market's listing
requirements. Provided that RanLOS AB (publ), applies ....

Company Registration Number , Nasdaq Stockholm , Nasdaq First North Growth Market , Nasdaq First North Growth Market Sweden , Registration Number , First North , Code Name , Certified Adviser , Aqurat Fondkommission , Diese Gold Aktie , Sichern Sie ,

Nexstim Plc: Approved delisting application regarding the

Company Announcement, Helsinki, 9 February 2023 at 6.15 PM (EET) Nexstim Plc: Approved delisting application regarding the secondary listing on the Nasdaq. ....

Eteläuomen Läi , United States , Aqurat Fondkommission , Mikko Karvinen , Company Certified Advisor Is Erik Penser Bank , Nexstim Plc , Nexstim Or Company , Company Announcement , Nasdaq First North Growth Market , Nasdaq First North Growth Market Finland , Nasdaq First North Growth Market Sweden , Euroclear Sweden , Euroclear Finland , Issuing Agent , Issuing Agent Aqurat Fondkommission , Certified Advisor , Erik Penser , Diagnostics Business , Navigated Brain Stimulation , Therapy Business , Navigated Brain Therapy , Helsinki Stock Exchange Nxtmh , Nexstim Oyj ,

Inside Information: Nexstim Plc applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden

08.02.2023 - Company Announcement, Inside Information, Helsinki, 8 February 2023 at 5 PM (EET) Inside Information: Nexstim Plc applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden Nexstim Plc shares . ....

United States , Aqurat Fondkommission , Mikko Karvinen , Company Certified Advisor Is Erik Penser Bank , Nexstim Plc , Nexstim Or Company , Nasdaq First North Growth Market Finland , Nasdaq First North Growth Market Sweden , Euroclear Sweden , Euroclear Finland , Issuing Agent Aqurat Fondkommission , Nasdaq Sweden , Certified Advisor , Erik Penser , Diagnostics Business , Navigated Brain Stimulation , Therapy Business , Navigated Brain Therapy , Nasdaq First North Growth Market , Inside Information ,